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Abstract
Background: Currently, the TNM staging system is a widely accepted method for assessing the prognosis of the
disease and planning therapeutic strategies for cancer. Of the TNM system, the extent of lymph node involvement
is the most important independent prognostic factor for gastric cancer. The aim of our study is to evaluate the
survival and prognosis of gastric cancer patients with LN#12 or #13 involvement only and to assess the impact of
anatomic regions of primary gastric tumor on survival in this particular subset of patients.
Methods: Among data of 1,008 stage IV gastric cancer patients who received curative R0 gastrectomy, a total of
79 patients with LN#12 (n = 68) and/or #13 (n = 11) were identified. All patients performed gastrectomy with D2
or D3 lymph node dissection.
Results: In 79 patients with LN#12/13 involvement, the estimated one-, three- and five-year survival rate was
77.2%, 41.8% and 26.6% respectively. When we compared the patients with LN#12/13 involvement to those
without involvement, there was no significant difference in OS (21.0 months vs. 25.0 months, respectively; P =
0.140). However, OS was significantly longer in patients with LN#12/13 involvement only than in those with M1
lymph node involvement (14.3 months; P = 0.001). There was a significant difference in survival according to
anatomic locations of the primary tumor (lower to mid-body vs. high body or whole stomach): 26.5 vs. 9.2 months
(P = 0.009). In Cox proportional hazard analysis, only N stage (p = 0.002) had significance to predict poor survival.
Conclusion: In this study we found that curatively resected gastric cancer patients with pathologic involvement of
LN #12 and/or LN #13 had favorable survival outcome, especially those with primary tumor location of mid-body
to antrum. Prospective analysis of survival in gastric cancer patients with L N#12 or #13 metastasis is warranted
especially with regards to primary tumor location.
Background
In Korea, gastric cancer is one of the most common
causes of cancer-related death [1]. Currently, the tumor,
node, metastasis (TNM) staging system is a widely
accepted method for assessing the prognosis of the dis-
ease and planning therapeutic strategies [2]. Of the
TNM system, the extent of lymph node involvement is
the most important independent prognostic factor for
gastric cancer [3]. These prerequisites were taken into
account in the new TNM classification established in
2002 by the Union Internationale Contra le Cancer
(UICC) and American Joint Committee on Cancer
(AJCC). The 4th N-classification was based on the sites
of lymph node metastasis (less than or greater than 3cm
from the primary tumor) [4,5], whereas in 5th (1997)
and 6th (2002) TNM editions, the N staging was based
on the number of metastatic lymph nodes [6-9].
In the 6th edition of AJCC TNM classification [7],
however, metastasis to intra-abdominal lymph nodes,
such as hepatoduodenal, retropancreatic, mesenteric,
and para-aortic, are still categorized as distant metas-
tases. In support of this, Roder et al also categorized
hepatoduodenal ligament lymph node involvement as
distant metastasis [10]. In Japanese Gastric Cancer
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Association (JGCA) N-classification, every single lymph
node was numbered as station (#1 to #112) and grouped
by anatomical position [11]. According to the Japanese
classification, hepatoduodenal lymph node is further
numbered as station 12 (#12) and sub-classified as #12a
(left hepatoduodenal lymph node) and #12b, p (posterior
hepatoduodenal lymph node). Any lymph node stations
greater than #12b are considered group 3 or distant
metastases, and subsequently being categorized as stage
IV gastric cancer.
Despite of such classification, several studies have
demonstrated favorable survival in subsets of patients
with lymph node metastases only. Chung et al. reported
favorable outcomes of 5-year survival reaching 47.2% in
a subgroup of gastric cancer patients with lymph node
#12 to #14 metastases only [12], which is considerably
higher than those reported for the historical control
[13,14]. One of the plausible explanations for favorable
survival in this particular group of patients may owe to
different lymphatic drainage system depending on vary-
ing anatomic sites of the stomach. Upper third lympha-
tic vessels drain along left gastric, posterior gastric and
splenic artery; whereas the lower third drains via com-
mon hepatic and superior mesenteric artery. Middle
third stomach has a mixed drainage in both ways. All
these vessels are eventually connected to the para-aortic
lymphatic network [15-17]. Hence, the anatomic site of
gastric cancer may be important when categorizing
lymph node stations as distant metastases.
The aim of our study is to evaluate the survival and
prognosis of gastric cancer patients with LN#12 or #13
involvement only and to assess the impact of anatomic
regions of primary gastric tumor on survival in this sub-
set of patients.
Methods
We reviewed surgical records and pathologic data of
5,687 patients with gastric adenocarcinoma who under-
went gastrectomies between January 1995 and Decem-
ber 2002 at Samsung Medical Center. All of the
included patients were restaged according to the 6th edi-
tion of AJCC and UICC [7,9]. In addition metastatic
lymph node stations were classified according to the 2nd
English edition of Japanese classification of gastric carci-
noma [11]. Among these, curative R0 resection was per-
formed in 1,008 stage IV patients including 79 patients
with pathologically confirmed hepatoduodenal lymph
node involvement (LN#12, n = 68) and/or LN#13 (n =
11) only. The outcomes of the 1,008 stage IV patients
who received curative gastric resection will be reported
elsewhere: in brief, the median age was 57 years (range,
25-75 years), and the estimated median overall survival
(OS) was 20.1 months. All patients received gastric
resection and D2 or D3 lymphadenectomy. While our
department policy usually recommends removal of
LN#12 and #13, pathologic examination of LN#12a
from the other nodes of the hepatoduodenal ligament
was seldom performed. Macroscopic findings of tumor
and microscopic tumor growth patterns were described
by Bormann type and Lauren classification, respectively.
Written informed consent was given by all patients
prior to surgery according to institutional guidelines,
and the study was approved by the Samsung Medical
Center (Seoul, Korea) institutional review board and any
ethical approval was not required. After gastrectomy,
two-thirds of the patients were treated with postopera-
tive adjuvant chemotherapy (57%) or chemoradiotherapy
(10%). While our department policy usually recom-
mends adjuvant treatment if the tumor stages Ib to IV,
decisions regarding postoperative treatment were indivi-
dualized by the treating physician. Chemotherapy regi-
mens were mostly cisplatin-based doublets, and
chemoradiotherapy consisted of 45 Gy of radiation with
leucovorin and 5-fluorouracil.
The starting point of OS was the day of gastric resection.
Time to death, whatever the cause, was used to calculate
OS. Investigation of the relationship between the lymph
node status and OS was conducted using univariate and
multivariate analyses. Survival curves and their confidence
intervals (CI) were calculated according to the Kaplan-
Meier method. The log rank test was used to assess the
statistical differences between groups, and the Chi-square
test was applied to assess differences in the distribution of
patients among groups. To identify the factors that might
be of independent significance in influencing the OS, Cox
proportional regression model was fitted.
Results
When the 1,008 stage IV gastric cancer patients were
divided according to LN#12/13 involvement only or
others, there were no differences in the baseline charac-
teristics including age, sex, histological grades and post-
operative treatment. The demographic and
histopathologic data of the 79 patients with lymph node
#12/13 involvement are provided in Table 1. The most
common site of primary tumor was antrum (63%), fol-
lowed by mid-body (23%), upper body (11%), and the
whole stomach (3%). Type of macroscopic finding was
Bormann type III (66%) in two-thirds, and approxi-
mately half of the patients had diffuse type in Lauren
classification. The distributions of T stage were as fol-
lows: T1 (0%), T2 (38%), T3 (52%), and T4 (10%). With
a median follow-up duration of 30 months, the esti-
mated median OS was 21.0 months (95% CI, 12.6-29.5
months). The patients had an estimated one-, three- and
five-year survival rate of 77.2%, 41.8% and 26.6% respec-
tively (Figure 1) and median disease-free survival was
28.5 months (Figure 2). When we compared the patients
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with LN#12/13 involvement to those without involve-
ment (i.e., T4 and/or N3 disease), there was no signifi-
cant difference in OS (21.0 months vs. 25.0 months,
respectively; P = 0.140). However, OS was significantly
longer in patients with LN#12/13 involvement only than
in those with M1 lymph node involvement (14.3
months; P = 0.001).
There was a significant difference in survival according
to anatomic locations of the primary tumor (lower to
mid-body vs. high body or whole stomach): 26.5 (95%
C.I; 10.6 - 42.3) months vs. 9.2 (95% C.I; 0.0 - 19.7)
months, respectively (P = 0.009) (Figure 3). However,
there were no significant differences in clinical variables
between the two tumor location groups except for types
of surgery of the extent of lymph node dissection due to
anatomic locations (Table 2). No significant difference
in the distribution of N stage was observed (p = 0.066).
In the univariate analysis applied to 79 LN#12/13
patients, OS was significantly longer in patients with
low to mid body tumors (26.5 months) than in those with
high body or whole stomach tumors (9.2 months,
P = 0.012). Other factors associated with longer OS were
Bormann type (I-II vs. III-IV, P = 0.031), N stage
(p < 0.001), type of gastrectomy (p = 0.014), and extent of
surgery (p = 0.006) (Table 3). In Cox proportional hazard
analysis, only N stage (p = 0.002) retained its statistical sig-
nificance to predict prognosis (Table 4). The anatomic
location of primary gastric tumor did not significantly
influence on survival of gastric cancer patients with
LN#12 and/or LN#13 involvement at multivariate level
(P = 0.906).
Discussion
In this study, we found that curatively resected gastric
cancer patients with pathologic involvement of LN #12
and/or LN #13 had favorable survival outcome, espe-
cially those with primary tumor location of mid-body to
antrum. To the best of our knowledge, there are no pre-
vious reports focusing on LN #12 and LN #13 involve-
ments in gastric cancer. According to the UICC/AJCC
6th edition [7,9], hepatoduodenal lymph node (LN #12)
and retropancreatic lymph node (LN#13) are categorized
as distant (M1) metastatic lymph node. Although limited
by inherent bias from retrospective analyses, our study
showed that LN #12 and/or LN #13 pathologic metas-
tases pursue discrete natural history apart from meta-
static M1 disease [13,14]. Furthermore, there are several
lines of evidence to support that gastric cancer with
metastatic lymph nodes only have more favorable clini-
cal outcome when compared to those with distant
metastasis. Five-year survival rate of pN3 gastric cancer
Table 1 Patient characteristics
Clinical variables Patient No (%)
Sex (Number)
Male 53 (67.1)
Female 26 (32.9)
Age (years)
Median 57
Range 25 - 75
ECOG performance status (Number)
0 10 (12.7)
1 68 (86.1)
2 1 (1.3)
Bormann type (Number)
I 0
II 17 (21.5)
III 52 (65.8)
IV 10 (12.7)
Lymph node dissection (Number)
D2 76 (96.2)
D3 3 (3.8)
Lauren classification (Number)
Intestinal 20 (25.3)
Diffuse 38 (48.1)
Mixed 4 (5.1)
Unknown 17 (21.5)
Histological grade
Well to moderate 23 (29.1)
Poor to undifferentiated 56 (70.9)
T staging (Number)
T1 0
T2 30 (38.0)
T3 41 (51.9)
T4 8 (10.1)
N staging (Number)
N1 14 (17.7)
N2 25 (31.6)
N3 40 (50.6)
Metastatic lymph node station (Number)
#12 69 (87.3)
#13 10 (12.7)
Post-operation treatment (Number)
None 21 (26.6)
Chemotherapy 48 (60.8)
Chemo-radiation 8 (10.1)
Unknown 2 (2.5)
Primary site (Number)
Upper body 9 (11.4)
Mid-body 18 (22.8)
Lower body 50 (63.3)
Whole stomach 2 (2.5)
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which was defined according to the 2002 AJCC staging
system ranged between 10.5% and 13% in previous stu-
dies [18,19]. Based on our study, five-year overall survi-
val rate of patients with LN#12 and/or LN#13 positive
gastric cancer with primary tumor at antrum to body
was 29.4%. These survival rate is comparable to that
reported for curatively resected stage IIIA or IIIB gastric
cancer as a historical cohort group [20]. Furthermore,
we previously reported outcomes of postoperative
treatment in gastric cancer to find the five-year survival
rate was <15% in stage IV patients [21].
One of the plausible explanations for significant discre-
pancy in survival between antral and cardial stomach can-
cer with hepatoduodenal lymph node and retropancreatic
lymph node may owe to different lymphatic drainage sys-
tem. The antral stomach cancer cells may drain into hepa-
toduodenal lymph node at earlier stage when compared
with those located at cardia for instance. The statistical
Figure 1 Overall survival. Kaplan-Meier overall survival curve. The
median overall survival was 21.0 (95% C.I; 12.6-29.5) months.
Figure 2 Disease-free survival. Kaplan-Meier disease-free survival
curve. The median disease-free survival was 28.5 (95% C.I; 14.7 - 42.3).
Figure 3 Survival according to primary site. a. Overall survival
according to primary site The median overall survival of lower &
mid-body was 26.5 (95% C.I; 10.6-42.3) months and that of high
body & whole stomach was 9.2 (95% C.I; 0.0-19.7) months
(p = 0.009). b. Disease-free survival according to primary site
The median relapse free survival of lower & mid-body was 31.5
(95% C.I; 12.6-50.4) months and that of high body & whole stomach
was 13.2 (95% C.I; 11.8-14.6) months (p = 0.106).
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Table 2 Patients’ characteristics according to primary sites
Low & mid-body (n = 68) High body & whole stomach (n = 11) P value
Age (mean) 56.2 57.9 0.524
Sex 0.262
Male 44 (35.3%) 9 (81.8%)
Female 24 (64.7%) 2 (18.2%)
ECOG performance status 0.780
0 8 (11.8%) 2 (18.2%)
1 59 (86.8%) 9 (81.8%)
2 1 (1.5%) 0
Bormann type 0.033
I 0 0
II 16 (23.5%) 1 (9.1%)
III 46 (67.6%) 6 (54.5%)
IV 6 (8.8%) 4 (36.4%)
Lauren classification 0.527
Intestinal 17 (25.0%) 3 (23.7%)
Diffuse 31 (45.6%) 7 (63.6%)
Mixed 4 (5.9%) 0
Unknown 16 (23.5%) 1 (9.1%)
Histological grade 0.390
Well to moderate 21 (30.9%) 2 (18.2%)
Poor to undifferentiated 47 (69.1%) 9 (81.8%)
Type of gastrectomy < 0.001
Total gastrectomy 26 (38.2%) 11 (100%)
Subtotal gastrectomy 42 (61.8%) 0
Extent of surgery < 0.001
Resection of spleen 9 (13.2%) 6 (54.5%)
Resection of distal pancreas 2 (2.9%) 1 (9.1%)
Resection of spleen, pancreas 0 2 (18.2%)
T staging 0.543
T1 0 0
T2 27 (39.7%) 3 (27.3%)
T3 35 (51.5%) 6 (54.5%)
T4 6 (8.8%) 2 (18.2%)
N staging 0.066
N1 14 (20.6%) 0
N2 23 (33.8%) 2 (18.2%)
N3 31 (45.6%) 9 (81.8%)
No. of dissected LNs (mean) 43.3 52.8 0.157
Metastatic lymph node station 0.701
#12 59 (86.8%) 10 (90.9%)
#13 9 (13.2%) 1 (9.1%)
Post-operation treatment 0.553
None 17 (25.0%) 4 (36.4%)
Chemotherapy 41 (60.3%) 7 (63.6%)
Chemo-radiation 8 (11.8%) 0
Unknown 2 (2.9%) 0
Lymph node dissection 0.007
D2 67 (98.5%) 9 (81.8%)
D3 1 (1.5%) 2 (18.2%)
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Table 3 Univariate analysis of prognostic factors for patients with metastatic lymph node positive gastric cancer
1 YSR 3 YSR Median OS (95% C.Ia) months H.R (95% C.Ia) P value
Age 0.461
< 65 82.1% 42.9% 25.6 (11.0 - 40.2) 1.0
> 65 65.2% 39.1% 19.2 (11.8 - 26.6) 1.232 (0.707 - 2.145)
Sex 0.204
Male 77.4% 47.2% 31.0 (15.2 - 46.9) 1.0
female 76.9% 30.8% 16.1 (11.9 - 20.2) 1.416 (0.828 - 2.421)
ECOG P.S 0.464
0 80.0% 40.0% 20.9 (0.0 - 49.6) 1.0
1 76.5% 42.7% 21.0 (12.2 - 29.8) 0.776 (0.381 - 1.582)
2 100% 0% 13.9 (13.9 - 13.9) 2.304 (0.285 - 18.624)
Primary site 0.012
Low & mid-body 82.4% 45.6% 26.5 (10.6 - 42.3) 1.0
High body & whole stomach 45.5% 18.2% 9.2 (0.0 - 19.7) 2.417 (1.216 - 4.806)
Bormann type 0.031
I
II 82.4% 58.8% 52.9 1.0
III 78.9% 42.3% 21.7 (7.8 - 35.6) 1.845 (0.895 - 3.803)
IV 60.0% 10.0% 13.0 (9.8 - 16.1) 3.521 (1.379 - 8.991)
Lauren classification 0.207
Intestinal 75.0% 30.0% 16.3 (15.7 - 16.8) 1.0
Diffuse 78.9% 57.9% 38.9 (31.0 - 46.8) 0.659 (0.344 - 1.233)
Mixed 75.0% 25.0% 14.1 (0.0 - 29.0) 0.920 (0.266 - 3.181)
Unknown 76.5% 23.5% 15.5 (12.3 - 18.7) 1.274 (0.622 - 2.610)
Histological grade 0.954
Well to moderate 86.9% 39.1% 20.8 (16.4 - 25.2) 1.0
Poor to undifferentiated 73.2% 42.9% 21.7 (5.9 - 37.5) 1.017 (0.578 - 1.787)
Type of gastrectomy 0.014
Total gastrectomy 70.3% 29.3% 17.1 (13.2 - 21.1) 1.913 (1.143 - 3.203)
Subtotal gastrectomy 83.3% 52.4% 36.6 (13.9 - 59.3) 1.0
Extent of surgery 0.006
None 81.4% 49.2% 34.9 (16.4 - 53.4) 1.0
Resection of spleen 60.0% 20.0% 13.0 (9.7 - 16.2) 2.937 (1.604 - 5.337)
Resection of distal pancreas 66.7% 33.3% 16.1 (0.0 - 34.9) 1.353 (0.327 - 5.606)
Resection of spleen, pancreas 100% 0% 18.1 1.953 (0.466 - 8.195)
T staging 0.116
T1
T2 80.0% 56.7% 38.9 (3.9 - 73.9) 1.0
T3 75.6% 31.7% 19.1 (14.3 - 23.8) 1.797 (1.010 - 3.198)
T4 75.0% 37.5% 16.1 (0.0 - 32.6) 1.861 (0.775 - 4.468)
N staging < 0.001
N1 92.9% 71.4% 59.6 (32.9 - 86.3) 1.0
N2 88.0% 60.0% 52.2 (35.4 - 69.0) 1.121 (0.470 - 2.674)
N3 65.0% 20.0% 14.8 (9.7 - 19.9) 3.870 (1.770 - 8.463)
No. of dissected LNs 0.810
< 40 75.8% 42.4% 25.6 (4.7 - 46.6) 1.065 (0.637 - 1.781)
> 40 78.3% 41.3% 20.8 (11.1 - 30.5) 1.0
Metastatic lymph node station 0.230
#12 76.8% 39.1% 20.8 (12.2 - 29.4) 1.0
#13 80.0% 60.0% 47.7 (0.4 - 95.0) 0.596 (0.256 - 1.388)
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significance of primary tumor site should be further vali-
dated in larger series of patients. Considering a marked
survival discrepancy between the two groups, LN#12
or#13 metastasis should be further categorized according
to primary tumor locations in future staging system.
Because lymph node metastases occur relatively early
in gastric cancer, regional lymphadenectomy is the stan-
dard surgical procedure in addition to radical gastrect-
omy [1]. However, the extent of lymphadenectomy to
achieve the optimal outcome is still controversial, and
there is no worldwide consensus. Controversy exists
regarding the extent of lymph node dissection, and
whether it should be limited to the perigastric lymph
nodes (D1) or include the regional lymph nodes outside
the perigastric area (D2) [22]. The appropriate extent of
lymph-node dissection for gastric cancer continues to be
debated. Radical lymphadenectomy did not increase
long-term survival after curative gastrectomy in either
the landmark Medical Research Council trial [23] or in
the Dutch [24] gastric trial. However, many proponents
of radical lymphadenectomy report benefit of radical or
extended radical lymphadenectomy. In a randomized
trial comparing D1 to D2/D3 lymph node dissection,
patients with D3 dissection showed an absolute overall
survival benefit of 5.9% (95% CI; 7.3-19.1, log-rank p =
0.041) when compared with the control group [25].
Recently, another study demonstrated survival benefit of
D2 or greater lymaphadenectomy over D1 surgery and
concluded that given the nodal diffusion in their gastric
cancer patients, extended lymphadenectomy is still a
rationale to obtain radical resection [15].
Given a considerable difference in survival according
to lymph node stations and primary tumor sites,
extended lymphadenectomies may also be crucial in
accurately staging the tumor. The LN#12 and higher
stations are not generally removed in D1 dissection and
in such case, there is a chance of misleading migration
to a lower stage. Although criticized by postoperative
complications in D2 or higher lymphadenectomies
[23,24], recent studies showed no difference in the inci-
dence of major complications or mortality between D1
and D2 dissections [26,27]. Notably, there was no signif-
icant difference in quality of life (QOL) after gastrect-
omy with D1 and D2/D3 lymphadenectomies [28].
Therefore, gastrectomy with extended lymphadenectomy
may be beneficial not only in terms of survival but also
accurate pathologic N staging.
This study is limited by small number of patients and
intrinsic bias from retrospective analysis in nature. Our
result should be interpreted with caution because it repre-
sents only a small group of patients with gastric cancer
and the LN#12a and other lymph nodes of the hepatoduo-
denal ligament were not evaluated separately. Prospective
evaluation of outcomes in subset of gastric cancer patients
with LN#12 or #13 metastasis is definitely warranted espe-
cially with regards to primary tumor location.
Conclusions
In this study, we found that curatively resected gastric
cancer patients with pathologic involvement of LN #12
and/or LN #13 had favorable survival outcome, espe-
cially those with primary tumor location of mid-body to
antrum.
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